Search Results - "Hermann, Robert C."

PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer by PATEL, Jyoti D, SOCINSKI, Mark A, GUBA, Susan C, JINGYI LIU, FRIMODT-MOLLER, Bente, JOHN, William J, OBASAJU, Coleman K, PENNELLA, Eduardo J, BONOMI, Philip, GOVINDAN, Ramaswamy, GARON, Edward B, REYNOLDS, Craig H, SPIGEL, David R, OLSEN, Mark R, HERMANN, Robert C, JOTTE, Robert M, BECK, Thaddeus, RICHARDS, Donald A

“…PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of…”
Get full text

Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099 by LYNCH, Thomas J, PATEL, Taral, PAUTRET, Virginie, WEBER, Martin R, WOYTOWITZ, Donald, DREISBACH, Luke, MCCLEOD, Michael, HEIM, William J, HERMANN, Robert C, PASCHOLD, Eugene, IANNOTTI, Nicholas O, DAKHIL, Shaker, GORTON, Steven

“…PURPOSE To evaluate the efficacy of cetuximab plus taxane/carboplatin (TC) as first-line treatment of advanced non-small-cell lung cancer (NSCLC). PATIENTS AND…”
Get full text

Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer by KHAMBATA-FORD, Shirin, HARBISON, Christopher T, HART, Lowell L, AWAD, Melissa, XU, Li-An, HORAK, Christine E, DAKHIL, Shaker, HERMANN, Robert C, LYNCH, Thomas J, WEBER, Martin R

“…PURPOSE The anti-epidermal growth factor receptor (EGFR) antibody cetuximab is efficacious in multiple tumor types. Patient selection with markers predictive…”
Get full text

Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer by BENDELL, Johanna C, NEMUNAITIS, John, VUKELJA, Sasha J, HAGENSTAD, Christopher, CAMPOS, Luis T, HERMANN, Robert C, SPORTELLI, Peter, GARDNER, Lesa, RICHARDS, Donald A

“…In a multicenter, double-blind phase II trial, we compared the efficacy and safety of perifosine plus capecitabine (P-CAP) with placebo plus capecitabine (CAP)…”
Get full text

Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network by HAINSWORTH, John D, LITCHY, Sharlene, BARTON, John H, HOUSTON, Gerry Ann, HERMANN, Robert C, BRADOF, James E, GRECO, F. Anthony

“…To assess the efficacy and toxicity of first-line single-agent rituximab, followed by re-treatment with rituximab at 6-month intervals, in previously untreated…”
Get full text

A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer by BERLIN, Jordan, BENDELL, Johanna C, GRAHAM, Richard A, BRAY, Gordon L, LOW, Jennifer A, HART, Lowell L, FIRDAUS, Irfan, GORE, Ira, HERMANN, Robert C, MULCAHY, Mary F, ZALUPSKI, Mark M, MACKEY, Howard M, YAUCH, Robert L

“…Vismodegib, a Hedgehog pathway inhibitor, has preclinical activity in colorectal cancer (CRC) models. This trial assessed the efficacy, safety, and…”
Get full text

Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2―Negative Advanced Breast Cancer That Progressed during or after Bevacizumab by SCHWARTZBERG, Lee S, TAUER, Kurt W, BELL-MCGUINN, Katherine, KIRSHNER, Jeffrey J, EISENBERG, Peter, EMANUELSON, Richard, KEATON, Mark, LEVINE, Ellis, MEDGYESY, Diana C, QAMAR, Rubina, STARR, Alexander, SUNHEE KWON RO, HERMANN, Robert C, LOKKER, Nathalie A, HUDIS, Clifford A, MAKARI-JUDSON, Grace, ISAACS, Claudine, THADDEUS BECK, J, KAKLAMANI, Virginia, STEPANSKI, Edward J, RUGO, Hope S, WEI WANG

“…We assessed adding the multikinase inhibitor sorafenib to gemcitabine or capecitabine in patients with advanced breast cancer whose disease progressed…”
Get full text

Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer by Spigel, David R, Patel, Jyoti D, Reynolds, Craig H, Garon, Edward B, Hermann, Robert C, Govindan, Ramaswamy, Olsen, Mark R, Winfree, Katherine B, Chen, Jian, Liu, Jingyi, Guba, Susan C, Socinski, Mark A, Bonomi, Philip

“…Treatment impact on quality of life (QoL) informs treatment management decisions in advanced nonsquamous non-small-cell lung cancer (NS NSCLC). QoL outcomes…”
Get more information

Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non–Small-Cell Lung Cancer by Reynolds, Craig H, Patel, Jyoti D, Garon, Edward B, Olsen, Mark R, Bonomi, Philip, Govindan, Ramaswamy, Pennella, Eduardo J, Liu, Jingyi, Guba, Susan C, Li, Shi, Spigel, David R, Hermann, Robert C, Socinski, Mark A, Obasaju, Coleman K

“…Micro-Abstract The present exploratory analysis of the PointBreak trial showed no significant differences between African Americans and whites for overall…”
Get full text

Treatment of Accidental Intrathecal Methotrexate Overdose With Intrathecal Carboxypeptidase G2 by Widemann, Brigitte C., Balis, Frank M., Shalabi, Aiman, Boron, Matthew, O'Brien, Michelle, Cole, Diane E., Jayaprakash, Nalini, Ivy, Percy, Castle, Valerie, Muraszko, Karin, Moertel, Christopher L., Trueworthy, Robert, Hermann, Robert C., Moussa, Ali, Hinton, Stuart, Reaman, Gregory, Poplack, David, Adamson, Peter C.

“…The bacterial enzyme carboxypeptidase G2 (CPDG2) rapidly hydrolyzes methotrexate to inactive metabolites. We administered recombinant CPDG2 (2000 U)…”
Get full text

Neurological manifestations of Erdheim-Chester disease by Wright, R Alan, Hermann, Robert C, Parisi, Joseph E

“…Erdheim-Chester disease is a rare sporadic systemic histiocytic disease of unknown aetiology that affects multiple organ systems. The case records of all…”
Get full text

Development of a multidisciplinary program for evaluation and treatment of pancreatic cancer in a community healthcare system by Hermann, Robert C., Early, Scott, Goel, Sachin, Hart, Justin, Huertas, Magali, Khulman, Chad, Webb, Leigh, Wilson, Barbara J, Shroff, Sahir

“…Abstract only 303 Background: The incidence and mortality of pancreas cancer is rising in the United States. Only patients who are able to have complete (R0)…”
Get full text

Phase I/II study of neoadjuvant eribulin mesylate, carboplatin, and trastuzumab (ECH) for operable HER2 positive (HER2+) breast cancer by Schwartzberg, Lee Steven, Tauer, Kurt W., Hermann, Robert C., Nikolinakos, Petros G., Houts, Arthur C.

“…Abstract only…”
Get full text

Phase I/II study of neoadjuvant carboplatin, eribulin mesylate, and trastuzumab (ECH) for operable HER2 positive (HER2+) breast cancer by Schwartzberg, Lee Steven, Tauer, Kurt W., Hermann, Robert C., Nikolinakos, Petros G., Houts, Arthur C.

“…Abstract only TPS659 Background: Carboplatin, docetaxel and trastuzumab (TCH) regimen yields substantial pathologic complete response (pCR) in operable HER2+…”
Get full text

PD-L1, PD-1, and CTLA-4 as prognostic biomarkers in resected non-small cell lung cancer by Owonikoko, Taofeek Kunle, Kowalski, Jeanne, Kim, Sungjin, Dwivedi, Bhakti, Chen, Zhengjia, Behera, Madhusmita, Mayfield, William, Hermann, Robert C., Chen, Lieping, Khuri, Fadlo Raja, Ramalingam, Suresh S., Sica, Gabriel

“…Abstract only…”
Get full text

Human papillomavirus (HPV)-associated early stage non-small cell lung cancer (NSCLC) by Pillai, Rathi Narayana, Ragin, Camille, Sica, Gabriel, Behera, Madhusmita, Chen, Zhengjia, Kim, Sungjin, Mayfield, William, Hermann, Robert C., Saba, Nabil F., Gal, Anthony A, Khuri, Fadlo Raja, Ramalingam, Suresh S., Owonikoko, Taofeek Kunle

“…Abstract only 7560 Background: HPV is an established risk factor for cervical and oropharyngeal cancer. It has been suggested as a potential risk factor for…”
Get full text

Translational research (TR) results from pointbreak: A randomized, open-label, phase III study of pemetrexed (Pem)+carboplatin (Cb)+bevacizumab (Bev) followed by maintenance pem+bev (Pem Arm) versus paclitaxel (Pac)+cb+bev followed by maintenance bev (Pac Arm) in patients (pts) with stage IIIB or IV nonsquamous non-small cell lung cancer (ns-NSCLC) by Garon, Edward B., Patel, Jyoti D., Myrand, Scott, Nguyen, Tuan, Reynolds, Craig H., Spigel, David R., Hermann, Robert C., Liu, Jingyi, Guba, Susan C., Govindan, Ramaswamy, Socinski, Mark A., Bonomi, Philip

“…Abstract only 8086 Background: Results of PointBreak were previously reported. Correlative tissue TR results are presented. Methods: Of 939 pts in the…”
Get full text

Exploratory analyses of efficacy and safety of pemetrexed (Pem) plus bevacizumab (Bev) and bev alone as maintenance therapy (MT) in patients (Pts) with stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC) by Patel, Jyoti D., Garon, Edward B., Govindan, Ramaswamy, Reynolds, Craig H., Spigel, David R., Olsen, Mark R., Hermann, Robert C., Liu, Jingyi, Guba, Susan C., Pennella, Eduardo J., Obasaju, Coleman K., Bonomi, Philip D., Socinski, Mark A.

“…Abstract only 8012 Background: In a phase III superiority study, Pem+carboplatin (Cb)+Bev followed by Pem+Bev improved PFS compared with paclitaxel…”
Get full text

Randomized phase III trial of pemetrexed (Pem)+carboplatin (Cb)+bevacizumab (Bev) followed by maintenance Pem+Bev (Pem arm) versus paclitaxel (Pac)+Cb+Bev followed by maintenance Bev (Pac arm) in patients (pts) with stage IIIb/IV nonsquamous non-small cell lung cancer (nsNSCLC) (POINTBREAK): African American (AA) subset by Reynolds, Craig H., Patel, Jyoti D., Garon, Edward B., Olsen, Mark R., Bonomi, Philip D., Govindan, Ramaswamy, Obasaju, Coleman K., Pennella, Eduardo J., Liu, Jingyi, Guba, Susan C., Spigel, David R., Hermann, Robert C., Socinski, Mark A.

“…Abstract only e19150 Background: AAs with lung cancer (LC) have shorter survival than Caucasians (Cs). Despite a higher LC incidence among AAs than Cs (74.7 vs…”
Get full text

Patient-reported outcomes from POINTBREAK: The randomized, open-label, phase III study of pemetrexed (pem) + carboplatin (cb) + bevacizumab (bev) followed by maintenance pem + bev versus paclitaxel (pac) + cb + bev followed by maintenance bev in patients with stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC) by Spigel, David R., Patel, Jyoti D., Reynolds, Craig H., Garon, Edward B., Hermann, Robert C., Govindan, Ramaswamy, Olsen, Mark, Winfree, Katherine B., Liu, Jingyi, Guba, Susan C., Socinski, Mark A., Bonomi, Philip

“…Abstract only 53 Background: Treatment (tx) impact on pt quality of life (QoL) informs pt and physician choices in the management of NSCLC. QoL, a secondary…”
Get full text